Given its role in the key pathological processes of Alzheimer’s disease—including cerebral hypoperfusion, neuroinflammation, and impaired synaptic plasticity—HIF-1α emerges as a promising therapeutic target. This evidence concerns the gene HIF1A and early-onset autosomal dominant Alzheimer disease.